|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
29 July 2022 |
|
Main ID: |
NCT04056481 |
|
Date of registration:
|
12/08/2019 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria
|
|
Scientific title:
|
Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria (AHP) |
|
Date of first enrolment:
|
January 7, 2020 |
|
Target sample size:
|
|
|
Recruitment status: |
No longer available |
|
URL:
|
https://clinicaltrials.gov/show/NCT04056481 |
|
Study type:
|
Expanded Access |
|
Study design:
|
|
|
Phase:
|
|
|
|
Countries of recruitment
|
|
Australia
|
Belgium
|
Canada
|
France
|
Germany
|
Luxembourg
|
Netherlands
|
Spain
|
|
Sweden
|
United States
| | | | | | |
|
Contacts
|
|
Name:
|
Medical Director |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Alnylam Pharmaceuticals |
| | |
|
Key inclusion & exclusion criteria
|
|
Health Condition(s) or Problem(s) studied
|
|
Source(s) of Monetary Support
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|